A CASE REPORT: RESIDUAL BREAST CANCER POST MODIFIED RADICAL MASTECTOMY WITH COMPLETE CHEMOTHERAPY FOLLOWED by ADJUVANT HORMONE THERAPY at IBNU SINA HOSPITAL
DOI:
https://doi.org/10.31004/prepotif.v9i2.49621Keywords:
Kanker payudara residual, mastektomi, kemoterapi, terapi hormon adjuvanAbstract
Tumor primer yang berulang merupakan masalah klinis yang sering terjadi beberapa bulan hingga tahun setelah pasien menjalani operasi atau kemoterapi. Kasus ini menggambarkan seorang pasien perempuan berusia 48 tahun yang datang dengan keluhan benjolan pada luka operasi di payudara kiri yang mulai dirasakan sekitar lima bulan sebelumnya. Benjolan tersebut awalnya kecil namun semakin membesar dengan disertai rasa nyeri tumpul yang datang dan pergi secara tiba-tiba tanpa dipengaruhi oleh posisi atau tekanan. Tidak ditemukan adanya perdarahan, nanah, maupun keluhan sistemik lain yang menyertai. Keluhan ini menggambarkan tumor baru yang berulang di lokasi yang sama, yang secara klinis didiagnosis sebagai kanker payudara kiri residif (Ca mammae sinistra residif). Sebagai tindakan intervensi, pasien menjalani prosedur pro-eksisi luas untuk mengangkat tumor tersebut. Evaluasi setelah tindakan menunjukkan pasien bebas gejala selama satu bulan pada pemeriksaan tindak lanjut. Kasus ini menegaskan pentingnya evaluasi ketat pada pasien kanker payudara pasca operasi atau kemoterapi guna mendeteksi tumor residual atau munculnya kekambuhan secara dini. Penanganan yang tepat dan pemantauan berkelanjutan sangat dibutuhkan untuk mencegah penyebaran kanker ke organ lain serta meningkatkan prognosis pasien. Studi kasus ini memberikan gambaran pentingnya kesadaran klinis terhadap risiko tumor berulang sehingga intervensi dapat dilakukan secara optimal untuk mengurangi komplikasi dan meningkatkan kualitas hidup pasien.References
Bick, U., & Helbich, T. H. (2019). Follow-up of patients with breast cancer: Imaging of local recurrence and distant metastases (pp. 167–178). https://doi.org/10.1007/978-3-030-11149-6_14
Crane, R., & Baker, C. R. (1999). Breast cancer treatment. Nurse Practitioner Forum Curr Top Commun, 10(3), 145–153.
De Melo Gagliato, D., Gonzalez-Angulo, A. M., Lei, X., et al. (2014). Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. Journal of Clinical Oncology, 32(8), 735–744. https://doi.org/10.1200/JCO.2013.49.7693
Finnegan, R. M., Elshazly, A. M., Schoenlein, P. V., & Gewirtz, D. A. (2022). Therapeutic potential for targeting autophagy in ER+ breast cancer. Cancers (Basel), 14(17), 1–14. https://doi.org/10.3390/cancers14174289
Fillon, M. (2022). Breast cancer recurrence risk can remain for 10 to 32 years. CA: A Cancer Journal for Clinicians, 72(3), 197–199. https://doi.org/10.3322/caac.21724
Gopal Menon, E. (2024). Breast cancer. StatPearls, NCBI. Published online.
Hu, X., Chen, W., Li, F., et al. (2023). Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance. Frontiers in Oncology, 13(April), 1–9. https://doi.org/10.3389/fonc.2023.1053125
Huang, J., Tong, Y., Chen, X., & Shen, K. (2021). Prognostic factors and surgery for breast cancer patients with locoregional recurrence: An analysis of 5,202 consecutive patients. Frontiers in Oncology, 11(October), 1–11. https://doi.org/10.3389/fonc.2021.763119
Ito, M., Amari, M., Sato, A., et al. (2024). Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. Breast, 73(November 2023), 103604. https://doi.org/10.1016/j.breast.2023.103604
Laili, K., Pratiwi, S. E., Trianto, H. F., & Fitrianingrum, I. (2024). The relationship between necrosis area with tumor size and lymph node metastasis of breast cancer patients in anatomical pathology laboratory at Dr Soedarso Pontianak General Hospital (pp. 272–281). Published online.
Mai, N., Myers, S., Shen, S., et al. (2024). Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer. NPJ Breast Cancer, 10(1), 1–7. https://doi.org/10.1038/s41523-024-00643-5
Muthmainnah, F. (2024). Faktor risiko kejadian kanker payudara pada wanita di RSUP Dr. Wahidin Sudirohusodo Kota Makassar tahun 2022. Published online.
Rantala, J., Seppä, K., Eriksson, J., et al. (2025). Incidence trends of early-onset breast cancer by lifestyle risk factors. BMC Cancer, 25(1). https://doi.org/10.1186/s12885-025-13730-y
Rossato de Almeida, G., Cesca, M. G., de Albuquerque e Rodrigues de Sousa, D. G., et al. (2024). Analysis of risk factors for recurrence within 12 months after surgery in patients with breast cancer receiving neoadjuvant therapy at a Brazilian cancer center. Journal of Clinical Oncology, 42(16_suppl), e13039–e13039. https://doi.org/10.1200/jco.2024.42.16_suppl.e13039
Sopik, V., Lim, D., Sun, P., & Narod, S. A. (2023). Prognosis after local recurrence in patients with early-stage breast cancer treated without chemotherapy. Current Oncology, 30(4), 3829–3844. https://doi.org/10.3390/curroncol30040290
Watanuki, R., Sakai, H., Takehara, Y., et al. (2025). Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: A retrospective cohort study in Japan (WJOG15721B). Breast Cancer, 32(4), 757–772. https://doi.org/10.1007/s12282-025-01700-y
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ollya Gaussyan Khalillah Akbar, Erlin Syahril, Agung Kurniawan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
